Hydroxycitric Acid
1. Identity: Chemical Nature, Botanical Source, and Common Preparations
Chemical Identity
Hydroxycitric acid (HCA) is a derivative of citric acid that is found in a variety of tropical plants including Garcinia cambogia and Hibiscus sabdariffa. There are four isomers: (+)- and (−)-hydroxycitric acid, and (+)- and (−)-allo-hydroxycitric acid. The (−)-hydroxycitric acid isomer is the one found in Garcinia. Hydroxycitric acid as such cannot be isolated directly from Garcinia fruits or Hibiscus sabdariffa fruits; it exists in both the open-chain acid form and the lactone form. The presence of two chiral centres in the molecule is exploited to construct molecular skeletons that are otherwise difficult to synthesize, demonstrating the lactone's use as a chiron.
Botanical Source
(−)-Hydroxycitric acid [(−)-HCA] is the principal acid of fruit rinds of Garcinia cambogia, Garcinia indica, and Garcinia atroviridis. Garcinia cambogia is a tree native to India and Southeast Asia, where it is commonly found in evergreen forests. The plant bears the synonymous accepted botanical name Garcinia gummi-gutta and is commonly called Malabar tamarind. Other organic acids such as tartaric acid, citric acid, and malic acid have been reported as minor constituents, but more recent reports state that the fruit contains only HCA and not citric acid or tartaric acid. HCA is a principal constituent (10–30%) of the dried fruit rind of Garcinia cambogia. Other relatively minor sources of HCA include the plant roselle (Hibiscus sabdariffa), apples, berries, plums, cherries, peaches, citrus fruits, carrots, cabbages, eggplants, coffee, and artichokes.
Commercial Forms and Preparations
Garcinia cambogia supplements are usually taken as capsules and are also often part of combination weight-loss supplements. Typically, HCA used in dietary weight-loss supplements is bound to calcium, which results in a poorly soluble (<50%) and less bioavailable form. The structural characteristics of a novel Ca²⁺/K⁺ bound (−)-HCA salt (HCA-SX, or Super CitriMax) make it completely water soluble and more bioavailable. The HCA-SX composition contains approximately 60% by weight of HCA, 11% by weight of calcium, and 16% by weight of potassium, with the remaining 13% consisting of water and other naturally occurring constituents of the fruit rind. Compositions including calcium HCA and sodium HCA salts have been sold commercially since 1994.
2. Traditional and Historical Use
The dried rind of Garcinia cambogia was used for centuries throughout Southeast Asia as a food preservative, flavoring agent, and carminative. The fruit rind is extensively used traditionally as a flavoring in fish curries due to its sharp, sour taste, and additional ethnobotanical uses include its use as a digestive and a traditional remedy to treat bowel complaints, intestinal parasites, and rheumatism. The fruit has been used as a tea in folk medicine for inflammation and stomach complaints, while the fruit rind has a history of traditional use as a food preservative.
The fruit rind of G. gummi-gutta is medicinally significant and is frequently used in Ayurvedic and traditional medicine for many diseases. In India, the dried fruit and rinds of the fruit are used in cooking. Known as Malabar tamarind, the plant is a popular traditional herbal medicine and is one of the well-known folk medicines reported for the treatment of obesity and incorporated in several nutraceuticals worldwide.
Various secondary metabolites such as organic acids — including hydroxycitric acid — flavonoids, terpenes, polysaccharides, and polyisoprenylated benzophenones (garcinol, xanthochymol, guttiferone, benzophenone, xanthone, biflavonoids, alkaloids, tannins, phenols, and saponins) isolated from G. gummi-gutta have diverse pharmacological activities.
3. Key Constituents and Mechanisms of Action
Primary Active Compound
(−)-HCA is the principal acid of the fruit rinds of Garcinia cambogia, Garcinia indica, and Garcinia atroviridis. It was shown to be a potent inhibitor of ATP citrate lyase (EC 4.1.3.8), which catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA. The inhibition of this reaction limits the availability of acetyl-CoA units required for fatty acid synthesis and lipogenesis during a lipogenic diet — that is, a diet high in carbohydrates.
Mechanism 1: Inhibition of ATP-Citrate Lyase and Lipogenesis
(−)-HCA is a competitive inhibitor of ATP citrate lyase, which converts citrate into oxaloacetate and acetyl-CoA. The reverse of this conversion is a step in the citric acid cycle. Extensive animal studies indicated that (−)-HCA suppresses fatty acid synthesis, lipogenesis, and food intake and induces weight loss. In vitro studies revealed the inhibition of fatty acid synthesis and lipogenesis from various precursors.
Mechanism 2: Glycogenesis and Energy Metabolism
The actions of (−) HCA increase the production and storage of glycogen (which is found in the liver, small intestine, and muscles of mammals) while reducing both appetite and weight gain. HCA serves to disinhibit the metabolic breakdown and oxidation of stored fat for fuel via its effects upon the compound malonyl-CoA, and gluconeogenesis takes place as a result of this action. The review by Jena et al. in the Journal of Agricultural and Food Chemistry covered the related biochemical pathways in depth, including effects on ketogenesis and promotion of lipid oxidation.
Mechanism 3: Serotonin-Mediated Appetite Suppression
HCA administration has been shown to increase serotonin levels, which in turn results in reduced appetite. In the rat brain cortex, a novel HCA extract (HCA-SX) was shown to increase the release and availability of radiolabeled serotonin ([³H]-5-HT), a neurotransmitter implicated in the regulation of eating behavior and appetite control. Furthermore, HCA-SX can inhibit [³H]-5-HT uptake and also increase 5-HT availability in isolated rat brain cortical slices in a manner similar to that of SSRIs. However, it is not certain that HCA's ability to curb appetite and reduce food intake derives entirely from these mechanisms.
Mechanism 4: Effects on Leptin Signaling
Another proposed mechanism of action is HCA's ability to down-regulate the obesity regulatory gene as determined by serum leptin levels. Leptin is a 167 amino-acid protein hormone encoded by the gene that regulates body weight; synthesized and secreted by adipocytes, it binds to receptors in the brain to inhibit food intake and increase energy expenditure. When receptor-binding activity is diminished (a condition called "leptin resistance"), plasma leptin levels increase and the leptin loses its ability to inhibit food intake.
Additional Proposed Mechanisms
More recently, HCA has been shown to be effective in suppressing appetite by modulating the levels of serotonin related to satiety, increasing fat oxidation, and reducing de novo lipogenesis, leading to reduced food consumption and body fat. The precise mechanisms of action of HCA remain largely unexplained in their totality.
4. Scientific Evidence by Area of Use
4a. Body Weight and Obesity
Overview of human clinical evidence: Results from clinical studies have shown both negative and positive antiobesity effects of Garcinia/hydroxycitric acid. Although several studies have found that the administration of G. cambogia extracts is associated with body weight and fat loss in both experimental animals and humans, caution is warranted when interpreting the results, as other randomized placebo-controlled clinical trials have not reported the same outcomes. Furthermore, most studies in humans have been conducted on small samples and mainly in the short term, and none has shown whether these effects persist beyond 12 weeks of intervention.
Key negative RCT — Heymsfield et al. (1998, JAMA): Heymsfield et al. (1998) published in JAMA a landmark study involving 135 overweight men and women (mean BMI approximately 32 kg/m²) randomized to Garcinia cambogia extract (50% HCA) or placebo. Participants took 1,000 mg of extract 30 minutes before each meal — a total daily dose of 3,000 mg extract containing 1,500 mg HCA. Over 12 weeks on a high-fiber, low-calorie diet, the Garcinia group did not lose significantly more weight or fat mass than the placebo group. It was subsequently suggested that the high-fiber diet may have impaired HCA absorption, though this remains speculative. Weight loss was similar in the two groups (3.2 vs 4.1 kg) and adverse event rates were similar, and none led to early discontinuations.
Systematic review and meta-analysis — Onakpoya et al. (2011, Journal of Obesity): The aim of this systematic review was to examine the efficacy of Garcinia extract (HCA) as a weight reduction agent using data from RCTs. Electronic and nonelectronic searches were conducted with no restrictions in language or time; two independent reviewers extracted the data and assessed methodological quality. Twenty-three eligible trials were identified and twelve were included; nine trials provided data suitable for statistical pooling. The meta-analysis revealed a small, statistically significant difference in weight loss favoring HCA over placebo (mean difference: −0.88 kg; 95% CI: −1.75, −0.00). Gastrointestinal adverse events were twice as common in the HCA group compared with placebo in one included study. It was concluded that RCTs suggest Garcinia extracts/HCA can cause short-term weight loss. The authors noted the effect size was small and of uncertain clinical significance.
Clinical study on obese subjects — Kuriyan et al. (RSC Advances, 2019): A clinical study on 100 obese individuals for a period of 3 months was performed, followed by a computational study aimed at investigating the effects of HCA treatment at anthropometric and plasma lipid profile levels. A detailed hepatic metabolic model was used to incorporate the effect of HCA at the metabolic pathway level. Significant reductions in body weight, triceps, subscapular, and mid-axillary measurements, as well as in serum triglyceride, cholesterol, HDL, and LDL levels, were observed following HCA dosage. However, the effect of HCA on humans has not been conclusive. A systematic review and meta-analysis found the magnitude of the weight-loss effect to be small and significant only in the short term. Further, lifestyle adjustments such as diet and exercise also influence the effect of these studies in an uncertain manner.
Bioavailability-optimized formulation — Preuss et al. (2004): At the end of 8 weeks with the HCA-SX (calcium-potassium salt) formulation, body weight and BMI decreased by 5.4%, LDL and triglycerides were reduced by 12.9% and 6.9% respectively, HDL levels increased by 8.9%, serum leptin levels decreased by 38%, serotonin levels increased by 44.5%, and urinary excretion of fat metabolites increased by 32–109%. Group B demonstrated similar beneficial changes, generally to a greater extent, and no significant adverse effects were observed.
Visceral fat accumulation RCT — Hayamizu et al. (2003): This study was performed according to a double-blind, placebo-controlled, parallel-group design. Randomization was performed by random number generation. The primary endpoint was the effects of 12 weeks of Garcinia cambogia extract administration on visceral fat accumulation. Subjects aged 20 to 65 years with a visceral fat area >90 cm² were enrolled, and were randomly assigned to receive treatment for 12 weeks with Garcinia cambogia (containing 1,000 mg of HCA per day) or placebo.
Overall assessment: While some animal and laboratory studies suggest that HCA might aid in weight loss by influencing metabolism and appetite, human clinical trials have produced mixed results, indicating that its effectiveness in this area remains uncertain.
4b. Blood Lipid Profile
Food intake, total cholesterol, LDL, triglycerides, and serum leptin levels were significantly reduced, while HDL and serotonin levels and excretion of urinary fat metabolites (a biomarker of fat oxidation) significantly increased in studies of HCA-SX. No significant adverse effects were reported. There is evidence from animal studies, but not from any rigorously designed human study, that ingested HCA will lower cholesterol blood lipid levels. Evidence for lipid effects in humans remains preliminary and is largely derived from small trials.
4c. Appetite and Satiety
HCA could trigger weight loss and inhibit lipogenesis through the suppression of citrate lyase enzymes. More recently, HCA has been shown to be effective in suppressing appetite by modulating the levels of serotonin related to satiety, increasing fat oxidation, and reducing de novo lipogenesis, leading to reduced food consumption and body fat. These findings derive predominantly from animal studies and a limited number of human trials. Evidence in humans is mixed; several smaller positive trials exist, but larger and methodologically more rigorous studies have not consistently confirmed appetite-suppressing effects.
4d. Non-Alcoholic Fatty Liver Disease (NAFLD)
A 2023 trial assessed the effects of a calorie-restricted diet (CRD) with HCA supplementation on appetite-regulating hormones, obesity indices, body composition, and appetite in women with nonalcoholic fatty liver disease (NAFLD). The study was carried out on 44 overweight/obese women with NAFLD who were randomly assigned to an intervention group (receiving individual CRD plus HCA tablets per day) or a control group (receiving only CRD) for eight weeks. At the end of the trial, significant reductions were found in most studied obesity indices in the intervention group, while only a significant decrease in waist circumference and waist-to-height ratio was found in the control group. Fat mass and muscle mass significantly decreased in the intervention group (p=0.044 and p=0.024, respectively), and the reduction in visceral fat in the intervention group was significantly greater than that in the control group (−0.49 kg vs −0.37 kg, p=0.024). Intra- and intergroup differences in serum leptin and adiponectin levels and their ratios before and after the trial were not statistically significant. The conclusion was that HCA plus a weight-loss diet could significantly reduce visceral adipose tissue without significant changes in serum leptin and adiponectin levels. This was a small trial (44 subjects) and results should be considered preliminary.
4e. Kidney Stone Prevention (Nephrolithiasis)
Some positive therapeutic evidence exists for HCA in treating and preventing kidney stones. HCA binds to calcium oxalate crystals, preventing them from adhering to and damaging kidney walls. Hydroxycitrate ingested by non-stone-forming humans at an often-recommended dose leads to substantial urinary excretion. In vitro assays using human urine reveal that hydroxycitrate is as effective an inhibitor of nucleation of calcium oxalate monohydrate as citrate. These findings support exploration of the clinical potential of hydroxycitrate as an alternative treatment to citrate for kidney stones.
HCA inhibits calcium oxalate crystallization by binding calcium ions and reducing crystal adhesion to renal tubular epithelial cells. HCA also mitigates oxidative stress and inhibits ferroptosis through the Nrf2 and GPX4 pathways, thereby protecting kidney tissue. Incorporating HCA into functional foods combined with probiotics and dietary fiber may reduce intestinal oxalate absorption, thereby lowering the risk of stone formation.
HCA inhibits lipid nephrotoxicity by activating the PPARα pathway, and it demonstrates better inhibition of calcium oxalate crystal formation compared to citric acid. In a rat metabolomics study, HCA demonstrated a protective effect against calcium oxalate crystal-induced kidney injury by modulating various metabolic pathways, and results suggest that HCA holds promise as a potential clinical therapeutic drug for both prevention and treatment of renal stones.
HCA can effectively inhibit the calcification of renal interstitial fibroblasts, reducing the risk of stone formation by inhibiting calcification-induced apoptosis and calcium salt deposition, and is considered a promising alternative drug for inhibiting renal stone formation. The evidence base for kidney stone prevention remains predominantly preclinical (animal and in vitro); large-scale human RCTs in this application are lacking.
5. Body Systems and Health Areas
- Metabolic/Adipose Tissue: Inhibition of de novo lipogenesis via ATP-citrate lyase; reduction in body fat and visceral adipose tissue in some trials.
- Gastrointestinal: Traditional use as a digestive and carminative; traditional remedy for bowel complaints and intestinal parasites.
- Central Nervous System / Neurotransmission: A proposed mechanism of action is HCA's ability to stimulate serotonin release and inhibit its reuptake. Serotonin (5-HT), a vital neurotransmitter, is involved in a wide range of behavioral functions including mood, sleep, and appetite control, and studies have shown that serotonin affects eating behavior and body weight.
- Hepatic / Liver: HCA acts primarily on hepatic ATP-citrate lyase to reduce acetyl-CoA availability for fat synthesis; in animal studies, markers of oxidative stress (malondialdehyde, protein carbonyl formation) were significantly lower in the kidney and liver of HCA-treated rats, and markers of inflammation (CRP, IL-6) were lower in plasma compared to controls.
- Renal / Urinary System: Inhibition of calcium oxalate crystal formation and adhesion; potential prevention of nephrolithiasis.
- Cardiovascular / Lipid Metabolism: Reduction in LDL and triglycerides and increase in HDL reported in some trials; animal evidence for cholesterol-lowering effects.
- Musculoskeletal: Traditional use as a remedy for rheumatism.
6. Dosage Forms and Reported Dosages
In the landmark 1998 Heymsfield JAMA trial, participants took 1,000 mg of Garcinia cambogia extract (50% HCA) 30 minutes before each meal, yielding a total daily dose of 3,000 mg extract containing 1,500 mg HCA.
In the Hayamizu double-blind RCT, subjects were instructed to take 3 tablets 30 minutes before each meal (9 tablets/day); the total daily dose was 1,667.25 mg of Garcinia cambogia extract, containing 1,000 mg of HCA.
In an eight-week double-blind, placebo-controlled trial of sixty overweight individuals, HCA was used at a dose of 440 mg three times daily.
Safety studies indicate that HCA-SX, a more bioavailable form, is unlikely to cause reproductive or developmental effects, and human trials with doses up to 2,800 mg/day reported no adverse effects, suggesting it is safe for consumption at those levels.
The acid is present to the extent of 20–30% in the dried fruit rinds of Garcinia cambogia, Garcinia atroviridis, and Garcinia indica, which are used for culinary purposes and available commercially in India.
Forms available in commercial products include: standardized dry fruit rind extract in capsules or tablets (the most common form); the calcium salt of HCA; the calcium-potassium salt formulation (HCA-SX / Super CitriMax); and liquid or powder preparations.
7. Safety Considerations and Interactions
General Safety Profile
In experimental animal studies at up to 25 times the human equivalency dose of HCA, there have been no reports of hepatotoxicity or other adverse effects. A formal safety assessment of a commercial potassium-calcium hydroxycitrate salt (60% HCA) by Soni et al. was designed specifically to look for potential hepatotoxicity. The gavage administration of this salt at doses up to 2,500 mg/kg per day for a period of 90 days did not lead to any significant adverse effects, including in the histological examinations of the livers of the test and control arms.
Gastrointestinal Adverse Effects
Gastrointestinal adverse events were twice as common in the HCA group compared with placebo in one included study in the Onakpoya 2011 systematic review. These included symptoms such as nausea, digestive discomfort, and diarrhea, but were generally mild.
Hepatotoxicity: A Contested Signal
Different cases of acute liver injury consequent to the use of food supplements containing Garcinia cambogia and hydroxycitric acid have been reported in the literature. A review of the literature analyzed herb-induced liver disease due to the use of hydroxycitric acid from the first alert from European regulatory authorities in 2009 to the most recent European food alerts from 2020 to 2021. Notably, in some cases, a relationship between hydroxycitric acid and hepatotoxicity was demonstrated.
Although a number of cases of hepatotoxicity are associated with the use of Hydroxycut weight-management products, it has been alleged that their effects are primarily due to the presence of HCA in the formulations. However, these products contain up to 20 different ingredients, some of which do not contain HCA. Case studies reported to date have not considered in depth the literature on the numerous animal and human studies that have been conducted on the safety and efficacy of HCA. No HCA-associated hepatotoxicity or treatment-related adverse effects have been reported in those studies, and thus it is premature to make definitive assumptions about causation.
A review in Critical Reviews in Food Science and Nutrition (2012) noted that adverse effects from Garcinia extracts are uncommon and mild in humans, but that the hepatotoxicity associated with the dietary supplement Hydroxycut has been purported to be caused by the Garcinia, although the association is unproven.
Garcinia cambogia has been associated with more severe side effects such as liver failure. Because it is often taken in combination supplements or studied as HCA extracted from the plant, it is difficult to be sure that Garcinia cambogia itself is the cause of these side effects.
Bioavailability and Formulation Interactions
Typically, HCA used in dietary weight-loss supplements is bound to calcium, which results in a poorly soluble (<50%) and less bioavailable form. The structural characteristics of the novel Ca²⁺/K⁺ bound (−)-HCA salt (HCA-SX, or Super CitriMax) make it completely water soluble and bioavailable. This difference in bioavailability has been proposed as a partial explanation for the divergent clinical results observed across trials.
Dosage levels, timing of administration, subject compliance, and bioavailability of HCA-SX significantly affect study results.
Diet-Supplement Interaction
In the Heymsfield JAMA trial, the Garcinia group on a high-fiber, low-calorie diet did not lose significantly more weight or fat mass than the placebo group. It was subsequently suggested that the high-fiber diet may have impaired HCA absorption, though this remains speculative.
High-Fat and Alcohol Diet Interactions
The tendency toward a reverse effect on high-fat and/or high-alcohol diets is a result of these diets making acetyl units available from beta-oxidation rather than from the export of citrate from the citric acid cycle, which is the more common metabolic path under normal conditions. Increasing the amount of HCA ingested and/or using more active forms of HCA reduces or eliminates the likelihood of a reverse effect under most conditions.
Regulatory Context
Regulatory concern about hydroxycitric acid in food supplements dates from a first alert from European authorities in 2009, with subsequent food safety alerts through 2020 and 2021. According to the 2026 WADA List of Prohibited Substances, Garcinia cambogia is not prohibited in sport.
References
Go back